復旦微電(688385.SH):擬向銀行等金融機構申請不超7.456億元綜合授信額度
格隆匯3月20日丨復旦微電(688385.SH)公佈,公司於2022年3月18日召開第八屆董事會第三十二次會議,審議通過了《關於申請2022年度綜合授信額度的議案》。
為滿足公司生產經營發展需要,公司及公司全資、控股子公司擬向銀行等金融機構申請不超過人民幣7.456億元的綜合授信額度。
綜合授信品種包括但不限於:流動資金借款、銀行承兑匯票、票據貼現、貿易融資、保函、信用證、項目資金借款等品種。
綜合授信額度期限為自董事會審議通過之日起十二個月內有效。在授信期限內,授信額度可循環使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.